Рroblem of the therapy use and risk ratio of the medication which stimulate erthropoesis in diabetic nephropathy
For more than 20 years to correct anemia in patients with chronic kidney disease (CKD) are used medications which stimulate erythropoesis (MSE). Currently in Russia there are multiple preparations of the MSE group: epoetin-α (epokrin, eralfon, Eprex), epoetin-β (Recormon), epoetin-ω (epomaks), darbepoetin-α (Aranesp), pegylated epoetin-β (Mircera ). Despite the fact that the study of the effectiveness of therapy MSE and its impact on the progression of CKD and cardiovascular disease was the subject of many studies, there is still no consensus regarding indications for treatment of MSE, the optimal therapeutic regimen and target hemoglobin levels.